Literature DB >> 8635666

Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells.

A Gugliucci1, M Bendayan.   

Abstract

The presence of excessive amounts of advanced glycation end products (AGE) in tissues or in the circulation may critically affect the progression of diabetic nephropathy. Circulating AGE levels, mainly in the form of small peptides, increase in diabetic patients or in patients with end-stage renal disease. This rise correlates with the severity of the nephropathy. However, so far little is known about the fate of AGE-proteins and AGE-peptides in renal tissue, and in order to elucidate this issue we undertook the present study. AGE-bovine serum albumin (AGE-BSA) and AGE-peptides were prepared, characterized by spectrophotometry, spectrofluorometry, chromatography and SDS-PAGE. AGE-peptides reacted in vitro with LDL producing biochemical and ultrastructural modifications. Using colloidal gold post-embedding immunoelectron microscopy with an anti-AGE antibody generated in our laboratory, we followed, in a short-term kinetic study, the cellular and sub-cellular localisation of circulating AGE-products throughout the nephron. AGE-peptides or AGE-BSA were injected into otherwise normal rats and detected by protein A-gold immuno-cytochemistry after 15, 30 or 45 min of circulation. Most of the AGE-BSA was found in the lumen of capillary vessels and distributed along the endothelial side of the glomerular basement membrane. Presence on mesangial matrix was also apparent. AGE-peptides were easily filtered and actively reabsorbed by the proximal convoluted tubule. At 15 min, little labelling was found in the glomerular wall. Instead, the labelling was present in the urinary space and microvilli of epithelial cells. Early endosomes displayed intense labelling as well. At 45 min, late endosomes and lysosomes added to the pattern of labelling. The distal tubule epithelial cells were devoid of labelling for any of the intervals studied. AGE-peptides but not AGE-BSA could be detected in the urine of injected rats. These observations point to participation of the endo-lysosomal apparatus of the proximal convoluted tubule to the disposal of AGE-peptides, while giving an ultrastructural support for a key role of the kidney in AGE catabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635666     DOI: 10.1007/bf00403957

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  48 in total

1.  Electron microscopy of negatively stained lipoproteins.

Authors:  T M Forte; R W Nordhausen
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Sequential flotation ultracentrifugation.

Authors:  V N Schumaker; D L Puppione
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor.

Authors:  H Vlassara; L Moldawer; B Chan
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

5.  Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat.

Authors:  T Mitsuhashi; H Nakayama; T Itoh; S Kuwajima; S Aoki; T Atsumi; T Koike
Journal:  Diabetes       Date:  1993-06       Impact factor: 9.461

6.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

7.  Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.

Authors:  H Vlassara; H Fuh; Z Makita; S Krungkrai; A Cerami; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

8.  The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide.

Authors:  A M Schmidt; R Mora; R Cao; S D Yan; J Brett; R Ramakrishnan; T C Tsang; M Simionescu; D Stern
Journal:  J Biol Chem       Date:  1994-04-01       Impact factor: 5.157

9.  Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo.

Authors:  H Vlassara; M Brownlee; A Cerami
Journal:  Diabetes       Date:  1988-04       Impact factor: 9.461

10.  Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions.

Authors:  F G Njoroge; L M Sayre; V M Monnier
Journal:  Carbohydr Res       Date:  1987-09-15       Impact factor: 2.104

View more
  39 in total

Review 1.  Glycoxidation and diabetic complications: modern lessons and a warning?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Enzymatic digestion and mass spectrometry in the study of advanced glycation end products/peptides.

Authors:  Annunziata Lapolla; Domenico Fedele; Rachele Reitano; Nadia Concetta Aricò; Roberta Seraglia; Pietro Traldi; Ester Marotta; Roberto Tonani
Journal:  J Am Soc Mass Spectrom       Date:  2004-04       Impact factor: 3.109

Review 3.  Uremic Toxicity of Advanced Glycation End Products in CKD.

Authors:  Andréa E M Stinghen; Ziad A Massy; Helen Vlassara; Gary E Striker; Agnès Boullier
Journal:  J Am Soc Nephrol       Date:  2015-08-26       Impact factor: 10.121

4.  Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium.

Authors:  S McFarlane; J V Glenn; A M Lichanska; D A C Simpson; A W Stitt
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

5.  The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculas.

Authors:  Yuko Yamada; Kazuko Ishibashi; Kazuki Ishibashi; Imran A Bhutto; Jane Tian; Gerard A Lutty; James T Handa
Journal:  Exp Eye Res       Date:  2005-12-20       Impact factor: 3.467

6.  Albumin and glycated albumin activate KIM-1 release in tubular epithelial cells through distinct kinetics and mechanisms.

Authors:  Ai Ing Lim; Loretta Y Y Chan; Sydney C W Tang; Kar Neng Lai; Joseph C K Leung
Journal:  Inflamm Res       Date:  2014-07-26       Impact factor: 4.575

7.  Advanced glycation end products in myocardial reperfusion injury.

Authors:  Peter Celec; Július Hodosy; Peter Jáni; Pavol Janega; Matúš Kúdela; Marta Kalousová; Johana Holzerová; Vojtech Parrák; Lukáč Halčák; Tomáš Zima; Martin Braun; Ivan Pecháň; Ján Murín; Katarína Šebeková
Journal:  Heart Vessels       Date:  2011-05-12       Impact factor: 2.037

8.  Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.

Authors:  Daniel P K Ng; Charles L Hardy; Wendy C Burns; Evelyne E Muggli; Nicole Kerr; Jane McCausland; Daine Alcorn; Timothy E Adams; Jeffrey D Zajac; Richard G Larkins; Marjorie E Dunlop
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

Review 9.  Can we target tubular damage to prevent renal function decline in diabetes?

Authors:  Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

10.  Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women.

Authors:  Richard D Semba; Luigi Ferrucci; Jeffrey C Fink; Kai Sun; Justine Beck; Mansi Dalal; Jack M Guralnik; Linda P Fried
Journal:  Am J Kidney Dis       Date:  2008-09-11       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.